<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SULFADIAZINE</span><br/>(sul-fa-dye'a-zeen)<br/><span class="topboxtradename">Microsulfon<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">sulfonamide antibiotic</span><br/><b>Prototype: </b>Sulfisoxazole<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Short-acting sulfonamide, slightly less soluble than sulfisoxazole. Exerts bacteriostatic effect by interfering with bacterial
         utilization of PABA, thereby inhibiting folic acid biosynthesis required for bacterial growth.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against a wide range of gram-positive and gram-negative microorganisms.</p>
<h1><a name="uses">Uses</a></h1>
<p>Used in combination with pyrimethamine for treatment of cerebral toxoplasmosis and chloroquine-resistant malaria.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to sulfonamides or to any ingredients in the formulation; pregnancy (category C).</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Application of lotion to denuded or debrided skin; lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Mild to Moderate Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO Loading Dose</span> 24 g loading dose <span class="rdroute">PO Maintenance Dose</span> 24 g/d in 46 divided doses<br/><span class="rdage">Child:</span> <span class="rdroute">PO Loading Dose</span>
<i>&gt;2 mo,</i> 75 mg/kg <span class="rdroute">PO Maintenance Dose</span> 150 mg/kg/d in 46 divided doses (max: 6 g/d)<br/><br/><span class="indicationtitle">Rheumatic Fever Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span>
<i> 500 mg/d; <i>&gt;30 kg,</i> 1 g/d<br/><br/><span class="indicationtitle">Toxoplasmosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 28 g/d divided q6h<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span>
<i>&gt;2 mo,</i> 100200 mg/kg/d divided q6h<br/><span class="rdage">Neonate:</span> <span class="rdroute">PO</span> 50 mg/kg q12h times 12 mo<br/></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Maintain sufficient fluid intake to produce urinary output of at least 1500 mL/24 h for children between 3000 and 4000 mL/24
            h for adults. Concomitant administration of urinary alkalinizer may be prescribed to reduce possibility of crystalluria and
            stone formation.
         </li>
<li>Store in tight, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, peripheral neuritis, peripheral neuropathy, tinnitus, hearing loss, vertigo, insomnia, drowsiness, mental depression,
      acute psychosis, ataxia, convulsions, kernicterus (newborns). <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea,</span> abdominal pains, hepatitis, jaundice, pancreatitis, stomatitis. <span class="typehead">Hematologic:</span> Acute hemolytic anemia (especially in patients with G6PD deficiency), <span class="speceff-life">aplastic anemia</span>, methemoglobinemia, <span class="speceff-life">agranulocytosis</span>, thrombocytopenia, leukopenia, eosinophilia, hypoprothrombinemia. <span class="typehead">Body as a Whole:</span> Headache, <span class="speceff-common">fever,</span> chills, arthralgia, malaise, allergic myocarditis, serum sickness, <span class="speceff-life">anaphylactoid reactions</span>, lymphadenopathy, local reaction following IM injection, fixed drug eruptions, diuresis, overgrowth of nonsusceptible organisms,
      LE phenomenon. <span class="typehead">Skin:</span> Pruritus, urticaria, rash, erythema multiforme including <span class="speceff-both">Stevens-Johnson syndrome, exfoliative dermatitis,</span> alopecia, photosensitivity, vascular lesions. <span class="typehead">Urogenital:</span>
<span class="speceff-common">Crystalluria,</span> hematuria, proteinuria, anuria, toxic nephrosis, reduction in sperm count. <span class="typehead">Metabolic:</span> Goiter, hypoglycemia. <span class="typehead">Special Senses:</span> Conjunctivitis, conjunctival or scleral infection, retardation of corneal healing (ophthalmic ointment). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">paba</span>-<span class="classification">containing local anesthetics</span> may antagonize sulfa's effects; <span class="classification">oral anticoagulants</span> potentiate hypoprothrombinemia; may potentiate <span class="classification">sulfonylurea</span>-induced hypoglycemia. May decrease concentrations of <b>cyclosporine;</b> may increase levels of <b>phenytoin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 36 h. <span class="typehead">Distribution:</span> Distributed to most tissues, including CSF; crosses placenta.  <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted in urine. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Baseline and periodic urine C&amp;S to determine drug effectiveness; with long-term therapy, CBC, Hct and Hgb.</li>
<li>Monitor hydration status.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Take drug exactly as prescribed. Do not alter schedule or dose; take total amount prescribed unless physician changes the
            regimen.
         </li>
<li>Drink fluids liberally unless otherwise directed.</li>
<li>Report early signs of blood dyscrasias (sore throat, pallor, fever) promptly to the physician.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>